Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Biorestorative Therapies, Inc. (BRTX : NSDQ)

• Company Description    BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's core programs consist of Disc/Spine Program and Metabolic Program. Disc/Spine Program consists of cell therapy candidate, brtxDISC(TM) is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. Metabolic Program consists of ThermoStem(R), developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. BioRestorative Therapies, Inc. is based in Melville, New York. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $1.17 Daily Weekly Monthly 20 Day Moving Average: 32,000 shares Shares Outstanding: 8.88 (millions) Market Capitalization: $10.43 (millions) Beta: 0.28 52 Week High: $2.55 52 Week Low: $0.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.86% 6.04% 12 Week -29.64% -30.77% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 40 MARCUS DRIVE SUITE 1 - MELVILLE,NY 11747 USA ph: 631-760-8100 fax: - ir@biorestorative.com http://www.biorestorative.com

• General Corporate Information    Officers Lance Alstodt - Chief Executive Officer; President and Chairman Robert E. Kristal - Chief Financial Officer Francisco Silva - Vice President; Research and Development and Direc Nickolay Kukekov - Director Patrick F. Williams - Director Peer Information Biorestorative Therapies, Inc. (CORR.) Biorestorative Therapies, Inc. (RSPI) Biorestorative Therapies, Inc. (CGXP) Biorestorative Therapies, Inc. (BGEN) Biorestorative Therapies, Inc. (GTBP) Biorestorative Therapies, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 090655606 SIC: 8090 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 8.88 Most Recent Split Date: 10.00 (0.00:1) Beta: 0.28 Market Capitalization: $10.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.35 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.27 Price/Cash Flow: - Price / Sales: 27.23 EPS Growth vs. Year Ago Period: -192.31% vs. Previous Quarter: -26.67% Sales Growth vs. Year Ago Period: -94.87% vs. Previous Quarter: -96.04% ROE 12/31/25 - - 09/30/25 - -231.08 06/30/25 - -137.00 ROA 12/31/25 - - 09/30/25 - -136.21 06/30/25 - -88.31 Current Ratio 12/31/25 - - 09/30/25 - 1.37 06/30/25 - 2.07 Quick Ratio 12/31/25 - - 09/30/25 - 1.37 06/30/25 - 2.07 Operating Margin 12/31/25 - - 09/30/25 - -3,268.93 06/30/25 - -1,667.60 Net Margin 12/31/25 - - 09/30/25 - -3,308.09 06/30/25 - -1,772.40 Pre-Tax Margin 12/31/25 - - 09/30/25 - -3,308.09 06/30/25 - -1,772.40 Book Value 12/31/25 - - 09/30/25 - 0.27 06/30/25 - 0.64 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©